AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 34983430 — intervention group
Group type: COMPARATOR
Intervention: PCT for predicting sepsis-3 with cutoff of 0.5 ng/mL
Number of subjects: 402
Study 34983488 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital Care Program (DCP) for acute MSK pain
Number of subjects: 343
Study 34983600 — intervention group
Group type: EXPERIMENTAL
Intervention: Early, biomarker-guided steroid dosing
Number of subjects: 0
Study 34983600 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 34983611 — intervention group
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 pneumonia group
Number of subjects: 1047
Study 34983611 — intervention group
Group type: COMPARATOR
Intervention: Influenza pneumonia group
Number of subjects: 1047
Study 34983621 — intervention group
Group type: EXPERIMENTAL
Intervention: PERC (Prostate Cancer Education & Resources for Couples)
Number of subjects: 0
Study 34983621 — intervention group
Group type: COMPARATOR
Intervention: Usual care plus the National Cancer Institute prostate cancer website (Control)
Number of subjects: 0
Study 34983621 — intervention group
Group type: EXPERIMENTAL
Intervention: PERC
Number of subjects: 0
Study 34983665 — intervention group
Group type: EXPERIMENTAL
Intervention: Checklist-based box system intervention
Number of subjects: 1062
Study 34983665 — intervention group
Group type: COMPARATOR
Intervention: Government-led maternal health program (Control)
Number of subjects: 1062
Study 34983671 — intervention group
Group type: EXPERIMENTAL
Intervention: First Phase Insulin Response (FPIR) in IvGTT
Number of subjects: 57
Study 34983671 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitoring (CGM)
Number of subjects: 57
Study 34983671 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of ZnT8 autoantibodies
Number of subjects: 57
Study 34983671 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting glucose and HbA1c
Number of subjects: 57
Study 34983749 — intervention group
Group type: EXPERIMENTAL
Intervention: Weighted fibre blankets (active)
Number of subjects: 100
Study 34983749 — intervention group
Group type: COMPARATOR
Intervention: Fibre blankets without weight (control)
Number of subjects: 100
Study 34983751 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein supplementation of ≥1.5 g/kg/day in addition to standard nutrition for 7 days or until PICU discharge.
Number of subjects: 70
Study 34983751 — intervention group
Group type: COMPARATOR
Intervention: Standard nutrition alone for 7 days or until PICU discharge.
Number of subjects: 70
Study 34983756 — intervention group
Group type: EXPERIMENTAL
Intervention: AI algorithm (CNN) used for lesion assessment during the postintervention period.
Number of subjects: 0
Study 34983756 — intervention group
Group type: EXPERIMENTAL
Intervention: AI-assisted decision by the registrar.
Number of subjects: 0
Study 34983756 — intervention group
Group type: COMPARATOR
Intervention: Preintervention period (no AI assessment) vs Postintervention period (AI assessment).
Number of subjects: 0
Study 34983756 — intervention group
Group type: EXPERIMENTAL
Intervention: AI algorithm's sensitivity, specificity, and agreement with histopathology or treating consultant dermatologists' classification.
Number of subjects: 0
Study 34983758 — intervention group
Group type: EXPERIMENTAL
Intervention: Cessation programme with 3-monthly visits
Number of subjects: 182
Study 34983758 — intervention group
Group type: COMPARATOR
Intervention: Control group with annual visits
Number of subjects: 182
Study 34983760 — intervention group
Group type: EXPERIMENTAL
Intervention: YC-PEM e-PRO measure and decision support tool
Number of subjects: 223
Study 34983760 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 223
Study 34983769 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher PHQ-9 scores
Number of subjects: 2365
Study 34983769 — intervention group
Group type: COMPARATOR
Intervention: Lower PHQ-9 scores
Number of subjects: 2365
Study 34984540 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugemalimab (1200 mg fixed dose once every 3 weeks)
Number of subjects: 207
Study 34984540 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugemalimab (monotherapy)
Number of subjects: 207
Study 34984540 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugemalimab (in combination with SOC chemotherapy)
Number of subjects: 207
Study 34985583 — intervention group
Group type: EXPERIMENTAL
Intervention: Childhood adversity (CA)
Number of subjects: 1084
Study 34985583 — intervention group
Group type: EXPERIMENTAL
Intervention: Adulthood adversity (AA)
Number of subjects: 1084
Study 34985583 — intervention group
Group type: EXPERIMENTAL
Intervention: Both childhood and adulthood adversity (CA and AA)
Number of subjects: 1084
Study 34985583 — intervention group
Group type: COMPARATOR
Intervention: Neither CA nor AA alone
Number of subjects: 1084
Study 34985974 — intervention group
Group type: EXPERIMENTAL
Intervention: Nanobody-functionalized cellulose
Number of subjects: 0
Study 34986183 — intervention group
Group type: EXPERIMENTAL
Intervention: dayzz smartphone app
Number of subjects: 0
Study 34986183 — intervention group
Group type: COMPARATOR
Intervention: waitlist control (no immediate access to the dayzz app)
Number of subjects: 0
Study 34986271 — intervention group
Group type: COMPARATOR
Intervention: Low-added sugar intake
Number of subjects: 1110
Study 34986409 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep endometriosis surgery
Number of subjects: 32
Study 34987618 — intervention group
Group type: EXPERIMENTAL
Intervention: Dendritic cell vaccines (DCV) plus neoadjuvant chemotherapy (NAC)
Number of subjects: 39
Study 34987618 — intervention group
Group type: COMPARATOR
Intervention: Neoadjuvant chemotherapy (NAC) alone
Number of subjects: 39
Study 34987619 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical and imaging examinations for axial involvement in PsA
Number of subjects: 0
Study 34987619 — intervention group
Group type: EXPERIMENTAL
Intervention: Imaging evaluations including radiography and magnetic resonance imaging of sacroiliac joints and spine
Number of subjects: 0
Study 34987619 — intervention group
Group type: EXPERIMENTAL
Intervention: Central clinical committee evaluation
Number of subjects: 0
Study 34987638 — intervention group
Group type: EXPERIMENTAL
Intervention: MMP-degradable and conductive hydrogel
Number of subjects: 0
Study 34988092 — intervention group
Group type: EXPERIMENTAL
Intervention: CytoSorb Therapy
Number of subjects: 0
Study 34988132 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral Water
Number of subjects: 0
Study 34988154 — intervention group
Group type: EXPERIMENTAL
Intervention: Transbronchial cryobiopsy (TBCB)
Number of subjects: 373
Study 34988234 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar radiofrequency microtenotomy (RFM)
Number of subjects: 38
Study 34988234 — intervention group
Group type: COMPARATOR
Intervention: Physical therapy (PT)
Number of subjects: 38
Study 34988237 — intervention group
Group type: EXPERIMENTAL
Intervention: Women
Number of subjects: 108
Study 34988237 — intervention group
Group type: COMPARATOR
Intervention: Men
Number of subjects: 108
Study 34988237 — intervention group
Group type: EXPERIMENTAL
Intervention: Both sexes
Number of subjects: 108
Study 34988237 — intervention group
Group type: EXPERIMENTAL
Intervention: Intercondylar notch width and lateral tibial slope
Number of subjects: 108
Study 34988299 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy for aggressive brain tumor (Group 1)
Number of subjects: 90
Study 34988299 — intervention group
Group type: EXPERIMENTAL
Intervention: No radiotherapy for low-grade brain tumor (Group 2)
Number of subjects: 90
Study 34988299 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group 3)
Number of subjects: 90
Study 34988480 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemoradiation treatment for esophageal cancer
Number of subjects: 55
Study 34988480 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-existing atrial fibrillation and a dilated left atrium
Number of subjects: 55
Study 34988480 — intervention group
Group type: EXPERIMENTAL
Intervention: Left ventricular (LV) systolic dysfunction
Number of subjects: 55
Study 34988480 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic cardiac evaluation prior to chemoradiation
Number of subjects: 55
Study 34988735 — intervention group
Group type: EXPERIMENTAL
Intervention: NBI-assisted diagnosis by endoscopist
Number of subjects: 451
Study 34988780 — intervention group
Group type: EXPERIMENTAL
Intervention: DiffCORE MR formulations (240 mg) administered in fasted and fed states
Number of subjects: 0
Study 34988780 — intervention group
Group type: EXPERIMENTAL
Intervention: DiffCORE MR-16 h formulation (120-960 mg)
Number of subjects: 0
Study 34988780 — intervention group
Group type: COMPARATOR
Intervention: Immediate-release formulation
Number of subjects: 0
Study 34988917 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment intensification (addition of new insulin, increase in insulin dosage, increase in insulin injection frequency, addition of non-insulin antihyperglycemic agents)
Number of subjects: 116
Study 34988917 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin intensification (increase in insulin dose, addition of new insulin, increase in insulin injection frequency)
Number of subjects: 116
Study 34988917 — intervention group
Group type: EXPERIMENTAL
Intervention: Increase in insulin dose
Number of subjects: 116
Study 34988917 — intervention group
Group type: EXPERIMENTAL
Intervention: Addition of new insulin
Number of subjects: 116
Study 34988917 — intervention group
Group type: EXPERIMENTAL
Intervention: Increase in insulin injection frequency
Number of subjects: 116
Study 34988917 — intervention group
Group type: EXPERIMENTAL
Intervention: HbA1c change from baseline
Number of subjects: 116
Study 34988917 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall HbA1c levels
Number of subjects: 116
Study 34989180 — intervention group
Group type: EXPERIMENTAL
Intervention: Felcisetrag 0.2-mg intravenous dose
Number of subjects: 0
Study 34989180 — intervention group
Group type: COMPARATOR
Intervention: Itraconazole 200-mg oral doses
Number of subjects: 0
Study 34989677 — intervention group
Group type: EXPERIMENTAL
Intervention: Calm app (meditation intervention)
Number of subjects: 83
Study 34989677 — intervention group
Group type: COMPARATOR
Intervention: POD (educational podcasts; control)
Number of subjects: 83
Study 34989701 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma transfusions
Number of subjects: 0
Study 34989701 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet transfusions
Number of subjects: 0
Study 34989701 — intervention group
Group type: EXPERIMENTAL
Intervention: Laboratory tests and physiologic triggers
Number of subjects: 0
Study 34989701 — intervention group
Group type: EXPERIMENTAL
Intervention: Product attributes
Number of subjects: 0
Study 34989842 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiologic scores for guiding individualized induction chemotherapy
Number of subjects: 542
Study 34989876 — intervention group
Group type: EXPERIMENTAL
Intervention: Cranial cervical parameters (McGregor slope, occipito-C2 angle, McGregor-C2 lordosis, C1-C2 lordosis)
Number of subjects: 2599
Study 34989876 — intervention group
Group type: EXPERIMENTAL
Intervention: Cranial cervical parameters in low PI
Number of subjects: 2599
Study 34989876 — intervention group
Group type: EXPERIMENTAL
Intervention: Caudal cervical parameters (C2-C7 lordosis, C7-slope, T1-slope)
Number of subjects: 2599
Study 34989876 — intervention group
Group type: EXPERIMENTAL
Intervention: Caudal arch lordosis after 35 years
Number of subjects: 2599
Study 34989876 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical alignment parameters
Number of subjects: 2599
Study 34989876 — intervention group
Group type: EXPERIMENTAL
Intervention: Caudal cervical arch
Number of subjects: 2599
Study 34989876 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlations between cervical parameters and thoracic kyphosis
Number of subjects: 2599
Study 34990002 — intervention group
Group type: EXPERIMENTAL
Intervention: Baricitinib 2-mg
Number of subjects: 0
Study 34990002 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 34990207 — intervention group
Group type: EXPERIMENTAL
Intervention: Serial 7 mental arithmetic stress test
Number of subjects: 23
Study 34990207 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold pressor test
Number of subjects: 23
Study 34990207 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical stimulation
Number of subjects: 23
Study 34990207 — intervention group
Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 23
Study 34990408 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose aerosol (LD) AdHu5Ag85A
Number of subjects: 31
Study 34990408 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose aerosol (HD) AdHu5Ag85A
Number of subjects: 31
Study 34990408 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular (i.m.) injection of AdHu5Ag85A
Number of subjects: 31
Study 34990411 — intervention group
Group type: EXPERIMENTAL
Intervention: Individuals with sickle cell disease (SCD)
Number of subjects: 74190
Study 34990411 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyurea use in individuals with SCD
Number of subjects: 74190
Study 34990411 — intervention group
Group type: COMPARATOR
Intervention: Controls (individuals without SCD)
Number of subjects: 74190
Study 34990764 — intervention group
Group type: EXPERIMENTAL
Intervention: Vasopressin and glucocorticoids
Number of subjects: 869
Study 34990778 — intervention group
Group type: EXPERIMENTAL
Intervention: Proton radiation therapy (PRT) at a dose of 54 Gy relative biological effectiveness
Number of subjects: 94
Study 34990810 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-amplifying mRNA (SAM) vaccine delivered by lipid nanoparticles (LNPs); two doses administered.
Number of subjects: 0
Study 34990810 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-amplifying mRNA (SAM) vaccine; two doses administered.
Number of subjects: 0
Study 34991141 — intervention group
Group type: EXPERIMENTAL
Intervention: BIC/FTC/TAF coformulated as a single daily pill for 28 days
Number of subjects: 52
Study 34991141 — intervention group
Group type: COMPARATOR
Intervention: Historical PEP regimens (not specified)
Number of subjects: 52
Study 34991479 — intervention group
Group type: EXPERIMENTAL
Intervention: Frailty assessment using the electronic Frailty Index (eFI)
Number of subjects: 2177656
Study 34991479 — intervention group
Group type: EXPERIMENTAL
Intervention: Analysis of health service use and care needs
Number of subjects: 2177656
Study 34991511 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotion regulation-enhanced group treatment
Number of subjects: 21
Study 34991520 — intervention group
Group type: EXPERIMENTAL
Intervention: OncoSNIPE® study intervention
Number of subjects: 600
Study 34991653 — intervention group
Group type: EXPERIMENTAL
Intervention: Galectin-3 plasma level measurement at ICU admission
Number of subjects: 2076
Study 34991660 — intervention group
Group type: EXPERIMENTAL
Intervention: Unmet medication needs
Number of subjects: 200
Study 34991660 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher proportion of unmet medication needs
Number of subjects: 200
Study 34991660 — intervention group
Group type: COMPARATOR
Intervention: Control group (no unmet medication needs)
Number of subjects: 200
Study 34991679 — intervention group
Group type: EXPERIMENTAL
Intervention: Ponatinib
Number of subjects: 449
Study 34991688 — intervention group
Group type: EXPERIMENTAL
Intervention: Dubbing language cinema-based therapy
Number of subjects: 54
Study 34991692 — intervention group
Group type: EXPERIMENTAL
Intervention: Seated social breaks
Number of subjects: 16
Study 34991692 — intervention group
Group type: EXPERIMENTAL
Intervention: Simple resistance activities
Number of subjects: 16
Study 34991692 — intervention group
Group type: EXPERIMENTAL
Intervention: Step-up activities
Number of subjects: 16
Study 34991701 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing (MI) and two mobile health (mHealth) components: oral health promotion messages and storytelling videos delivered using WhatsApp messenger
Number of subjects: 0
Study 34991701 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention applied)
Number of subjects: 0
Study 34991703 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg oral montelukast every 24 hours
Number of subjects: 0
Study 34991703 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 34991704 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin mass drug administration (MDA)
Number of subjects: 182
Study 34991704 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 182
Study 34991708 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab plus azacitidine
Number of subjects: 30
Study 34991824 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-PCI iFR ≥0.95
Number of subjects: 500
Study 34991824 — intervention group
Group type: COMPARATOR
Intervention: Post-PCI iFR <0.95
Number of subjects: 500
Study 34991824 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-PCI iFR ≥0.95 in highly symptomatic patients (baseline SAQ-AF score ≤60)
Number of subjects: 500
Study 34991824 — intervention group
Group type: COMPARATOR
Intervention: Post-PCI iFR <0.95 in highly symptomatic patients (baseline SAQ-AF score ≤60)
Number of subjects: 500
Study 34991828 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydra transcatheter aortic valve (THV)
Number of subjects: 157
Study 34991937 — intervention group
Group type: EXPERIMENTAL
Intervention: PCSK9 inhibitors (PCSK9-I) therapy
Number of subjects: 80
Study 34992051 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of marijuana
Number of subjects: 1997
Study 34992051 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of alcohol
Number of subjects: 1997
Study 34992051 — intervention group
Group type: EXPERIMENTAL
Intervention: Belief in public health measures
Number of subjects: 1997
Study 34992051 — intervention group
Group type: EXPERIMENTAL
Intervention: Graduate students
Number of subjects: 1997
Study 34992051 — intervention group
Group type: EXPERIMENTAL
Intervention: Students with ≥20 roommates
Number of subjects: 1997
Study 34992051 — intervention group
Group type: COMPARATOR
Intervention: Mental health status
Number of subjects: 1997
Study 34992051 — intervention group
Group type: COMPARATOR
Intervention: Average daily steps (Fitbit)
Number of subjects: 1997
Study 34992093 — intervention group
Group type: EXPERIMENTAL
Intervention: Andecaliximab monotherapy (800 mg IV Q2W)
Number of subjects: 18
Study 34992093 — intervention group
Group type: EXPERIMENTAL
Intervention: Andecaliximab in combination with nivolumab (800 mg IV Q2W)
Number of subjects: 18
Study 34992101 — intervention group
Group type: EXPERIMENTAL
Intervention: EQ-5D-3L intervention
Number of subjects: 266241
Study 34992101 — intervention group
Group type: COMPARATOR
Intervention: General population
Number of subjects: 266241
Study 34992118 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose naltrexone (LDN) 4.5 mg/day
Number of subjects: 120
Study 34992118 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 34992122 — intervention group
Group type: EXPERIMENTAL
Intervention: Postbirth follow-up recommendations compliance
Number of subjects: 249
Study 34992122 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk factors for non-compliance
Number of subjects: 249
Study 34992122 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk factors for unnecessary PED visits
Number of subjects: 249
Study 34992150 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuraxial anesthesia
Number of subjects: 11523
Study 34992150 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia
Number of subjects: 11523
Study 34992327 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart to Heart training intervention for foster and kinship caregivers
Number of subjects: 0
Study 34992372 — intervention group
Group type: EXPERIMENTAL
Intervention: Vortioxetine 10 mg
Number of subjects: 489
Study 34992372 — intervention group
Group type: EXPERIMENTAL
Intervention: Vortioxetine 20 mg
Number of subjects: 489
Study 34992372 — intervention group
Group type: COMPARATOR
Intervention: Vortioxetine 10 mg or 20 mg
Number of subjects: 489
Study 34992380 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary vocational rehabilitation program with lifestyle intervention
Number of subjects: 11
Study 34992575 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular treatment during on-hours
Number of subjects: 0
Study 34992575 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular treatment during off-hours
Number of subjects: 0
Study 34992825 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant therapy with camrelizumab, nab-paclitaxel, and carboplatin
Number of subjects: 40
Study 34992965 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregiver-reported physical aggression
Number of subjects: 170
Study 34992965 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregiver-reported sexual aggression
Number of subjects: 170
Study 34992965 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative incidence of physical aggression at 12 months
Number of subjects: 170
Study 34992965 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative incidence of sexual aggression at 12 months
Number of subjects: 170
Study 34993171 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 34993216 — intervention group
Group type: EXPERIMENTAL
Intervention: Alterations in the Gut Microbiota
Number of subjects: 0
Study 34993222 — intervention group
Group type: EXPERIMENTAL
Intervention: Very Low-Carbohydrate High-Fat Diet
Number of subjects: 0
Study 34993222 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training
Number of subjects: 0
Study 34993222 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 34993386 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin-sensitive patients
Number of subjects: 128
Study 34993386 — intervention group
Group type: COMPARATOR
Intervention: Aspirin-resistant patients
Number of subjects: 128
Study 34993388 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation
Number of subjects: 192
Study 34993388 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 192
Study 34993715 — intervention group
Group type: EXPERIMENTAL
Intervention: Single SSPE
Number of subjects: 224
Study 34993715 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple SSPE
Number of subjects: 224
Study 34993715 — intervention group
Group type: EXPERIMENTAL
Intervention: Incidental SSPE
Number of subjects: 224
Study 34993715 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptomatic SSPE
Number of subjects: 224